ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo

N. Moore,1 M. Moreno Gonzales,2 M. Stegall.1

1Department of Surgery, Division of Transplant Surgery and Department of Immunology, Mayo Clinic, Rochester, MN
2Department of Surgery, Division of Transplant Surgery, Mayo Clinic, Rochester, MN.

Meeting: 2015 American Transplant Congress

Abstract number: C12

Keywords: B cells, Bone marrow, FACS analysis, Mice

Session Information

Session Name: Poster Session C: Antigen Presenting Cells in Alloimmune Responses/B Cells and Antibody in Alloimmune Responses

Session Type: Poster Session

Date: Monday, May 4, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Receptor/ligand interactions in stromal microenvironments play important roles in the localization, development and survival of normal antibody-secreting plasma cells. The goal of the current study was to determine the impact of blocking CXCR4/CXCL12 interactions with plerixafor on the homeostasis of PCs in vivo. BALB/c mice were treated with plerixafor (up to 1 mg/kg x 10d). Blockade of CXCR4/CXCL12 mobilized a subpopulaton of splenic plasma cells into the peripheral blood. Bone marrow PCs did not appear to be mobilized by plerixafor. Total plasma cell numbers in the spleen and bone marrow remained constant, however, some plasma cells in both compartments appear to have been depleted and replaced by new ones. Splenic plasma cells from plerixafor-treated mice were more likely to undergo apoptosis soon after isolation suggesting subtle effects on the viability of these cells. However, blocking CXCR4/CXCL12 interactions did not enhance the depleting effects of the proteasome inhibitor, bortezomib. We conclude that CXCR4/CXCL12 interactions are important for the retention and longevity of a subpopulation of plasma cells in the spleen, but this interaction has minimal effect on plasma cells in the marrow. These data suggest that the use of plerixafor for the mobilization of hematopoietic stem cells should have minimal impact on antibody production of donors.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Moore N, Gonzales MMoreno, Stegall M. Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-cxcr4cxcl12-blockade-on-normal-plasma-cells-in-vivo/. Accessed May 30, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences